EMA - European Medicines Agency · March 30, 2023

EMA fast-track review of daraxonrasib for metastatic pancreatic cancer

Original title: EMA fast tracks review of a medicine for metastatic pancreatic cancer

EMA's CHMP has initiated a phased review of daraxonrasib for metastatic pancreatic cancer treatment.

Low obligation Product class Pharmaceuticals EU-wide Pharmaceuticals

EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased…

Read the official source ↗

Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.